STROBE Statement—Checklist of items that should be included in reports of ***cohort studies***

	Item No	Recommendation	PAGE
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	Abstract (page 7 of proof)
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract (page 7)
		RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included	Abstract (page 7)
		RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract	Abstract (page 7)
		RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract	Abstract (page 7)
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8
Objectives	3	State specific objectives, including any prespecified hypotheses	8
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8-9, Table 1
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	8-9
		(*b*) For matched studies, give matching criteria and number of exposed and unexposed	10
		RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.	8-9
		RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.	10
		RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.	NA – Linkage completed by ICES
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	10
		RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.	9-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	10
Bias	9	Describe any efforts to address potential sources of bias	9-10

Study size	10	Explain how the study size was arrived at	8-10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	11
		(*b*) Describe any methods used to examine subgroups and interactions	NA
		(*c*) Explain how missing data were addressed	NA
		(*d*) If applicable, explain how loss to follow-up was addressed	NA
		(*e*) Describe any sensitivity analyses	NA
		RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.	NA
		RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	NA – Performed by ICES
		RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided	10
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 11, Table 2
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
		RECORD 13.1: Describe in detail the selection of the persons included in the study (*i.e.,* study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Table 2, page 11
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 2, page 11
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	11, Table 3 supplemental
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 11, Figure 1, Figure 2
		(*b*) Report category boundaries when continuous variables were categorized	NA
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	12

Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12-13
		RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	12-13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Title page (page 4)
		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	Title page (page 4)

*Give information separately for exposed and unexposed groups.